A Prospective Study of t(4;14) Multiple Myeloma.
Lionel Karlin(Hôpital Lyon Sud), Bertrand Arnulf(Université Paris Cité), Jean Soulier(Centre National de la Recherche Scientifique), Raphaël Porcher(Hotel Dieu Hospital), Marion Malphettes(Hôpital Saint-Louis), Karim Belhadj(Hôpitaux Universitaires Henri-Mondor), Margaret Macro(Hôpital Cochin), Didier Bouscary(Université Paris Cité), Bouchra Asli(Hôpital Saint-Louis), David Ghez(Hôpital Necker-Enfants Malades), Jean‐Paul Fermand(Sorbonne Université), Jean‐Claude Brouet(Centre National de la Recherche Scientifique), Sylvain Choquet(Sorbonne Université)
Cited by 0
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k
Biologic and clinical significance of cryoglobulins
|The American Journal of Medicine|1974|1.7k
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k